loading
Cullinan Therapeutics Inc stock is traded at $12.58, with a volume of 786.32K. It is down -3.97% in the last 24 hours and down -24.99% over the past month. Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.
See More
Previous Close:
$13.10
Open:
$12.99
24h Volume:
786.32K
Relative Volume:
1.54
Market Cap:
$771.52M
Revenue:
-
Net Income/Loss:
$-153.16M
P/E Ratio:
-3.7329
EPS:
-3.37
Net Cash Flow:
$-134.48M
1W Performance:
-20.33%
1M Performance:
-24.99%
6M Performance:
-47.54%
1Y Performance:
+43.61%
1-Day Range:
Value
$12.50
$13.52
1-Week Range:
Value
$12.50
$16.20
52-Week Range:
Value
$7.64
$30.19

Cullinan Therapeutics Inc Stock (CGEM) Company Profile

Name
Name
Cullinan Therapeutics Inc
Name
Phone
617-410-4650
Name
Address
ONE MAIN STREET, CAMBRIDGE
Name
Employee
85
Name
Twitter
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
CGEM's Discussions on Twitter

Compare CGEM with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
CGEM 12.58 771.52M 0 -153.16M -134.48M -3.37
VRTX 451.23 115.74B 10.63B -479.80M -1.35B 13.33
REGN 743.35 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.82 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.79 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.14 24.49B 3.30B -501.07M 1.03B 11.54

Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades

Date Action Analyst Rating Change
May-01-24 Initiated Stifel Buy
Apr-15-24 Initiated William Blair Outperform
Feb-15-24 Initiated Wedbush Outperform
Jun-15-23 Initiated TD Cowen Outperform
Nov-21-22 Initiated BTIG Research Buy
Apr-27-21 Upgrade Morgan Stanley Equal-Weight → Overweight
Feb-02-21 Initiated Evercore ISI Outperform
Feb-02-21 Initiated Morgan Stanley Equal-Weight
Feb-02-21 Initiated SVB Leerink Outperform
Feb-01-21 Initiated H.C. Wainwright Buy
View All

Cullinan Therapeutics Inc Stock (CGEM) Latest News

pulisher
Nov 20, 2024

Cullinan Therapeutics Announces Q3 2024 Progress and Outlook - TipRanks

Nov 20, 2024
pulisher
Nov 20, 2024

What is Leerink Partnrs' Forecast for CGEM FY2025 Earnings? - MarketBeat

Nov 20, 2024
pulisher
Nov 15, 2024

Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 6.3%Time to Sell? - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Blue Owl Capital Holdings LP Adjusts Stake in Cullinan Therapeutics Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Cullinan advances lupus treatment with new clinical trial By Investing.com - Investing.com Canada

Nov 14, 2024
pulisher
Nov 14, 2024

Cullinan advances lupus treatment with new clinical trial - Investing.com

Nov 14, 2024
pulisher
Nov 14, 2024

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 - GlobeNewswire

Nov 14, 2024
pulisher
Nov 14, 2024

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager - The Bakersfield Californian

Nov 14, 2024
pulisher
Nov 14, 2024

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 - GlobeNewswire Inc.

Nov 14, 2024
pulisher
Nov 08, 2024

Cullinan Therapeutics' chief scientific officer sells $125,120 in stock By Investing.com - Investing.com Australia

Nov 08, 2024
pulisher
Nov 08, 2024

Cullinan Therapeutics' chief scientific officer sells $125,120 in stock - Investing.com India

Nov 08, 2024
pulisher
Nov 07, 2024

Cullinan Therapeutics: Q3 Earnings Snapshot - Darien Times

Nov 07, 2024
pulisher
Nov 07, 2024

Insider Sale: Chief Scientific Officer of Cullinan Therapeutics Inc (CGEM) Sells Shares - GuruFocus.com

Nov 07, 2024
pulisher
Nov 07, 2024

Cullinan Therapeutics Inc (CGEM) Quarterly 10-Q Report - Quartzy

Nov 07, 2024
pulisher
Nov 07, 2024

Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - GlobeNewswire

Nov 07, 2024
pulisher
Nov 07, 2024

Cullinan Therapeutics Advances Pipeline Despite $40.6M Loss; Maintains $639M Cash Position | CGEM Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 05, 2024

Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference - StockTitan

Nov 05, 2024
pulisher
Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition in Cullinan Therapeutics Inc - GuruFocus.com

Nov 05, 2024
pulisher
Nov 04, 2024

Cullinan Therapeutics to Present Preclinical Data for - GlobeNewswire

Nov 04, 2024
pulisher
Nov 04, 2024

Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024 - StockTitan

Nov 04, 2024
pulisher
Nov 03, 2024

Analysts Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Target Price at $31.67 - MarketBeat

Nov 03, 2024
pulisher
Oct 30, 2024

FY2027 Earnings Forecast for CGEM Issued By Leerink Partnrs - MarketBeat

Oct 30, 2024
pulisher
Oct 24, 2024

Cullinan Therapeutics (NASDAQ:CGEM) Receives New Coverage from Analysts at UBS Group - MarketBeat

Oct 24, 2024
pulisher
Oct 22, 2024

Exchange Traded Concepts LLC Sells 2,961 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Oct 22, 2024
pulisher
Oct 22, 2024

SG Americas Securities LLC Sells 70,115 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat

Oct 22, 2024
pulisher
Oct 22, 2024

Newco trend watch: Clusters of launches point to areas undergoing derisking - BioCentury

Oct 22, 2024
pulisher
Oct 20, 2024

cullinan oncology, inc. Earnings dates - RTTNews

Oct 20, 2024
pulisher
Oct 18, 2024

Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 3.2%Here's Why - MarketBeat

Oct 18, 2024
pulisher
Oct 17, 2024

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Short Interest Update - MarketBeat

Oct 17, 2024
pulisher
Oct 17, 2024

Cullinan Oncology stock gets 5% price target increase, H.C. Wainwright remains bullish after FDA approval - Investing.com

Oct 17, 2024
pulisher
Oct 16, 2024

Cullinan Therapeutics (NASDAQ:CGEM) Trading Up 7%Here's Why - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

Cullinan Therapeutics' (CGEM) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

Cullinan Therapeutics Gets FDA Approval for Lupus Treatment Study - Marketscreener.com

Oct 16, 2024
pulisher
Oct 16, 2024

Cullinan Therapeutics Receives U.S. FDA Clearance of - GlobeNewswire

Oct 16, 2024
pulisher
Oct 16, 2024

Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus - StockTitan

Oct 16, 2024
pulisher
Oct 11, 2024

How did Cullinan Therapeutics Inc (CGEM) fare last session? - US Post News

Oct 11, 2024
pulisher
Oct 11, 2024

Cullinan Therapeutics Inc [CGEM] Records 200-Day SMA of $17.94 - Knox Daily

Oct 11, 2024
pulisher
Oct 09, 2024

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of "Buy" from Brokerages - MarketBeat

Oct 09, 2024
pulisher
Oct 06, 2024

Algert Global LLC Reduces Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat

Oct 06, 2024
pulisher
Oct 02, 2024

The Potential Rise in the Price of Cullinan Therapeutics Inc (CGEM) following insiders activity - Knox Daily

Oct 02, 2024
pulisher
Oct 02, 2024

Metric Deep Dive: Understanding Cullinan Therapeutics Inc (CGEM) Through its Ratios - The Dwinnex

Oct 02, 2024
pulisher
Oct 02, 2024

Results from Cullinan Therapeutics Inc (CGEM) show potential - US Post News

Oct 02, 2024
pulisher
Sep 30, 2024

Perceptive Advisors LLC Takes Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat

Sep 30, 2024
pulisher
Sep 28, 2024

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Sold by Blue Owl Capital Holdings LP - MarketBeat

Sep 28, 2024
pulisher
Sep 27, 2024

Lynx1 Capital Management LP Buys New Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat

Sep 27, 2024
pulisher
Sep 26, 2024

There is no doubt that Cullinan Therapeutics Inc (CGEM) ticks all the boxes. - SETE News

Sep 26, 2024
pulisher
Sep 26, 2024

Deerfield Management Company L.P. Series C Increases Stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat

Sep 26, 2024
pulisher
Sep 25, 2024

Cullinan Therapeutics Inc (CGEM)’s stock price in review: A technical analysis - US Post News

Sep 25, 2024
pulisher
Sep 24, 2024

Quarterly Metrics: Quick and Current Ratios for Cullinan Therapeutics Inc (CGEM) - The Dwinnex

Sep 24, 2024
pulisher
Sep 24, 2024

CGEM’s Debt-to-Equity Ratio at 0.00: What It Means for Cullinan Therapeutics Inc’s Future - The InvestChronicle

Sep 24, 2024
pulisher
Sep 24, 2024

Paradigm Capital Management Inc. NY Has $39.46 Million Stock Holdings in Concentrix Co. (NASDAQ:CNXC) - MarketBeat

Sep 24, 2024

Cullinan Therapeutics Inc Stock (CGEM) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$71.05
price up icon 0.69%
$18.62
price down icon 6.90%
$36.94
price down icon 0.94%
$364.33
price up icon 1.00%
$194.26
price up icon 3.46%
$102.14
price down icon 4.00%
Cap:     |  Volume (24h):